LIGAND PHARMACEUTICALS (LGND)
US53220K5048 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 277.1M 48.66% | 196.2M -29.20% | 131.314M -33.07% | 166.59M 26.86% | 190.81M 14.54% | 225.31M 18.08% | 255.73M 13.50% | 328.11M 28.30% | 410.13M 25.00% | 508.57M 24.00% | |
| EBITDA YoY % growth | 130M 277.91% | 54.5M -58.08% | 46.342M -14.97% | 76.357M 64.77% | 121.22M 58.75% | 173.09M 42.79% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | 78.9M 806.90% | 3M -96.20% | 9.821M 227.37% | 14.05M 43.06% | 73.7M 424.56% | 110.44M 49.85% | 98.23M -11.06% | 114.84M 16.91% | 149.7M 30.36% | 193.26M 29.10% | |
| Operating Margin | 28.47% | 1.53% | 7.48% | 8.43% | 38.62% | 49.02% | 38.41% | 35.00% | 36.50% | 38.00% | |
| EPS YoY % growth | 6.42 41.10% | 4.28 -33.33% | 6.10 42.52% | 5.74 -5.84% | 6.07 5.69% | 7.00 15.26% | 9.85 40.82% | N/A | N/A | N/A |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | 1.21 -12.68% | 1.25 3.98% | 1.40 -0.19% | 1.65 -10.57% | 1.84 52.64% |
| Revenue Q2Q % growth | 39.79M 41.60% | 36.378M 17.43% | 42.149M 1.49% | 47.27M -8.77% | 53.736M 35.05% |
| EBITDA Q2Q % growth | 20.307M -38.77% | 18.743M 59.47% | 26.877M 7.47% | 33.037M -12.06% | 39.99M 96.93% |
| EBIT Q2Q % growth | 9.913M 395.21% | 3.507M 17.37% | 9.627M 30.25% | 14.861M 35.65% | 20.697M 108.79% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 1.84 80.39% | 1.37 | 0.47 | 33.98% |
| Q2 2024 Q2Q % growth | 1.40 -1.41% | 1.08 | 0.32 | 29.98% |
| Q1 2024 Q2Q % growth | 1.20 -47.37% | 0.79 | 0.41 | 50.98% |
| Q4 2023 Q2Q % growth | 1.38 1.47% | 0.67 | 0.71 | 104.76% |
| Q3 2023 Q2Q % growth | 1.02 -22.14% | 0.62 | 0.40 | 63.93% |
| Q2 2023 Q2Q % growth | 1.42 37.86% | 0.65 | 0.77 | 117.61% |
| Q1 2023 Q2Q % growth | 2.28 293.10% | 0.91 | 1.37 | 150.03% |
| Q4 2022 Q2Q % growth | 1.36 -24.44% | 1.22 | 0.14 | 11.74% |
| Q3 2022 Q2Q % growth | 1.31 -17.09% | 0.44 | 0.87 | 197.43% |
| Q2 2022 Q2Q % growth | 1.03 -36.81% | 0.44 | 0.59 | 134.84% |
| Q1 2022 Q2Q % growth | 0.58 -58.87% | 0.67 | -0.09 | -13.41% |
| Q4 2021 Q2Q % growth | 1.80 11.11% | 1.40 | 0.40 | 28.81% |
| Q3 2021 Q2Q % growth | 1.58 51.92% | 1.06 | 0.52 | 49.42% |
| Q2 2021 Q2Q % growth | 1.63 63.00% | 1.39 | 0.24 | 17.36% |
| Q1 2021 Q2Q % growth | 1.41 58.43% | 1.15 | 0.26 | 22.88% |
| Q4 2020 Q2Q % growth | 1.62 128.17% | 1.01 | 0.61 | 60.43% |
| Q3 2020 Q2Q % growth | 1.04 112.24% | 1.00 | 0.04 | 3.86% |
| Q2 2020 Q2Q % growth | 1.00 47.06% | 0.78 | 0.22 | 28.97% |
| Q1 2020 Q2Q % growth | 0.89 -23.28% | 0.67 | 0.22 | 32.87% |
| Q4 2019 Q2Q % growth | 0.71 -58.24% | 0.65 | 0.06 | 8.42% |
| Q3 2019 Q2Q % growth | 0.49 -62.88% | 0.62 | -0.13 | -21.25% |
| Q2 2019 Q2Q % growth | 0.68 -73.75% | 0.56 | 0.12 | 21.77% |
| Q1 2019 Q2Q % growth | 1.16 -25.16% | 1.04 | 0.12 | 11.50% |
| Q4 2018 Q2Q % growth | 1.70 | 1.24 | 0.46 | 36.61% |
| Q3 2018 Q2Q % growth | 1.32 | 1.05 | 0.27 | 26.13% |
| Q2 2018 Q2Q % growth | 2.59 | 2.39 | 0.20 | 8.51% |
| Q1 2018 Q2Q % growth | 1.55 | 1.31 | 0.24 | 17.98% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 51.812M 57.64% | 41.463M | 10.349M | 24.96% |
| Q2 2024 Q2Q % growth | 41.531M 57.52% | 33.522M | 8.009M | 23.89% |
| Q1 2024 Q2Q % growth | 30.978M -29.56% | 28.482M | 2.496M | 8.76% |
| Q4 2023 Q2Q % growth | 28.101M 3.89% | 26.23M | 1.871M | 7.13% |
| Q3 2023 Q2Q % growth | 32.868M -44.50% | 27.73M | 5.138M | 18.53% |
| Q2 2023 Q2Q % growth | 26.366M -54.08% | 26.248M | 118K | 0.45% |
| Q1 2023 Q2Q % growth | 43.979M 20.42% | 34.718M | 9.261M | 26.67% |
| Q4 2022 Q2Q % growth | 27.05M -62.67% | 39.952M | -12.902M | -32.29% |
| Q3 2022 Q2Q % growth | 59.22M -8.67% | 39.043M | 20.177M | 51.68% |
| Q2 2022 Q2Q % growth | 57.42M -32.19% | 38.489M | 18.931M | 49.19% |
| Q1 2022 Q2Q % growth | 36.52M -33.78% | 37.052M | -532K | -1.44% |
| Q4 2021 Q2Q % growth | 72.47M 3.54% | 66.625M | 5.845M | 8.77% |
| Q3 2021 Q2Q % growth | 64.84M 54.93% | 56.765M | 8.075M | 14.23% |
| Q2 2021 Q2Q % growth | 84.68M 104.44% | 71.901M | 12.779M | 17.77% |
| Q1 2021 Q2Q % growth | 55.15M 66.31% | 64.112M | -8.962M | -13.98% |
| Q4 2020 Q2Q % growth | 69.99M 159.22% | 55.177M | 14.813M | 26.85% |
| Q3 2020 Q2Q % growth | 41.85M 68.68% | 45.247M | -3.397M | -7.51% |
| Q2 2020 Q2Q % growth | 41.42M 65.75% | 32.019M | 9.401M | 29.36% |
| Q1 2020 Q2Q % growth | 33.16M -23.74% | 27.064M | 6.096M | 22.52% |
| Q4 2019 Q2Q % growth | 27M -54.69% | 25.588M | 1.412M | 5.52% |
| Q3 2019 Q2Q % growth | 24.81M -45.66% | 23.756M | 1.054M | 4.44% |
| Q2 2019 Q2Q % growth | 24.99M -72.25% | 21.434M | 3.556M | 16.59% |
| Q1 2019 Q2Q % growth | 43.48M -22.58% | 40.591M | 2.889M | 7.12% |
| Q4 2018 Q2Q % growth | 59.59M | 54.238M | 5.352M | 9.87% |
| Q3 2018 Q2Q % growth | 45.66M | 42.53M | 3.13M | 7.36% |
| Q2 2018 Q2Q % growth | 90.04M | 83.84M | 6.2M | 7.40% |
| Q1 2018 Q2Q % growth | 56.16M | 43.88M | 12.28M | 27.99% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -3.95% | -7.34% | 4.46% | 4.42% |
| Revenue | 0% | -0.31% | 2.99% | 6.26% |